biote Corp. Subsidiary Initiates Voluntary Recall of Hormone Pellets

summarizeResume

The voluntary recall by biote Corp.'s subsidiary, Asteria Health, due to potential metal particulate matter in hormone pellets, represents a notable financial and operational risk. While the company expects a one-time charge of $1.3 million in Q4 2025 for inventory write-off and an additional $1.0 million in 2026 for recall-related costs, the total estimated impact of $2.3 million is significant. The involvement of the FDA and the nature of the product (bioidentical hormones) elevate the seriousness of the event. Although management states they do not anticipate a material impact on their ability to supply practitioners, investors will closely monitor future disclosures for any unforeseen operational disruptions or reputational damage, especially given the stock is trading near its 52-week low.

check_boxEvenements cles

• Voluntary Product Recall Initiated

  F.H. Investments, Inc. (Asteria Health), a wholly-owned subsidiary of biote Corp., initiated a voluntary recall of specific lots of hormone pellets due to the potential presence of metal particulate matter.

• FDA Notified

  The recall, affecting products shipped between May 20, 2025, and January 19, 2026, is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).

• Estimated Financial Impact

  The company expects a one-time charge of approximately $1.3 million in Q4 2025 for inventory write-off and an additional $1.0 million in 2026 for recall-related costs.

• No Anticipated Material Operational Impact

  biote Corp. does not believe the recall will materially impact its ability to provide pellets to practitioner partners or their ability to service patients.

auto_awesomeAnalyse

The voluntary recall by biote Corp.'s subsidiary, Asteria Health, due to potential metal particulate matter in hormone pellets, represents a notable financial and operational risk. While the company expects a one-time charge of $1.3 million in Q4 2025 for inventory write-off and an additional $1.0 million in 2026 for recall-related costs, the total estimated impact of $2.3 million is significant. The involvement of the FDA and the nature of the product (bioidentical hormones) elevate the seriousness of the event. Although management states they do not anticipate a material impact on their ability to supply practitioners, investors will closely monitor future disclosures for any unforeseen operational disruptions or reputational damage, especially given the stock is trading near its 52-week low.